CRIS Profile
Curis, Inc., a biotechnology firm based in Lexington, Massachusetts, specializes in the research and development of innovative therapies targeting various human cancers across the United States. Established in 2000, the company focuses on advancing clinical stage drug candidates that show promising potential in treating challenging malignancies.
At the forefront of Curis' pipeline is Emavusertib, an oral small molecule currently undergoing Phase 1/2 clinical trials. This drug candidate is designed for the treatment of non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes, reflecting Curis' commitment to addressing critical unmet medical needs in oncology.
Additionally, Curis continues to expand its portfolio with Fimepinostat, an oral dual inhibitor targeting HDAC and PI3K enzymes. This innovative approach is aimed at patients with MYC-altered diffuse large B-cell lymphoma, showcasing the company's dedication to developing novel therapeutic modalities.
Through strategic collaborations with industry leaders such as F. Hoffmann-La Roche Ltd., Genentech Inc., and Aurigene Discovery Technologies Limited, Curis strengthens its capabilities in drug development and commercialization. These partnerships are pivotal in advancing promising candidates like Erivedge, an orally-administered hedgehog signaling pathway inhibitor for advanced basal cell carcinoma, and exploring new avenues in immuno-oncology and precision oncology. Curis, Inc. continues to drive innovation in cancer treatment, aiming to improve outcomes for patients worldwide.
|
